US 2020/0262913 A1Published application

Methods of treating pruritic disease with il-31 monoclonal antibodies

AssigneesZymoGenetics, Inc., Merck Serono S/A

InventorsKent Bondensgaard, Roland Beckmann

Life of this patent

Estimating the term…

Abstract

The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.

Claims28

Dependent claims

A method of treating a pruritic disease in a human patient comprising administering to the patient a therapeutically effective amount of a monoclonal antibody that specifically binds to human IL-31, wherein the antibody comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain and the light chain variable domain each comprise a complementarity determining region (CDR) and a framework region (FR),

wherein the heavy chain variable domain complementarity determining region comprises:
a) a CDR1 having the amino acid sequence of SEQ ID NO:1;
b) a CDR2 having the amino acid sequence of SEQ ID NO:2;
and
c) a CDR3 having the amino acid sequence of SEQ ID NO:3;
wherein the heavy chain variable domain framework region comprises:
d) a FR1 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:12;
e) a FR2 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:13;
f) a FR3 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:14;
and
g) a FR4 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:15;
wherein the wherein the light chain variable domain complementarity determining region comprises:
h) a CDR1 having the amino acid sequence of SEQ ID NO:5;
i) a CDR2 having the amino acid sequence of SEQ ID NO:6;
and
j) a CDR3 having the amino acid sequence of SEQ ID NO:7;
wherein the light chain variable domain framework region comprises:
k) a FR5 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:17;
l) a FR6 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:18;
m) a FR7 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:19;
and
n) a FR8 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:20;
and
wherein the pruritic disease is atopic dermatitis, contact dermatitis, dermatitis, prurigo nodularis, eczema, vitiligo, alopecia aerata, acne rosacea, acne vulgaris or bullous pemphigoid.

21 more elements

A method of treating a pruritic disease in a human patient comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising a monoclonal antibody that specifically binds to human IL-31 and a pharmaceutically acceptable carrier, wherein the antibody comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain and the light chain variable domain each comprise a complementarity determining region (CDR) and a framework region (FR),

wherein the heavy chain variable domain complementarity determining region comprises:
a) a CDR1 having the amino acid sequence of SEQ ID NO:1;
b) a CDR2 having the amino acid sequence of SEQ ID NO:2;
and
c) a CDR3 having the amino acid sequence of SEQ ID NO:3;
wherein the heavy chain variable domain framework region comprises:
d) a FR1 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:12;
e) a FR2 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:13;
f) a FR3 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:
14;
and
g) a FR4 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:15;
wherein the light chain variable domain complementarity determining region comprises:
h) a CDR1 having the amino acid sequence of SEQ ID NO:5;
i) a CDR2 having the amino acid sequence of SEQ ID NO:6;
and
j) a CDR3 having the amino acid sequence of SEQ ID NO:7;
wherein the light chain variable domain framework region comprises:
k) a FR5 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:17;
l) a FR6 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:18;
m) a FR7 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:19;
and
n) a FR8 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:20;
and
wherein the pruritic disease is atopic dermatitis, contact dermatitis, dermatitis, prurigo nodularis, eczema, vitiligo, alopecia aerata, acne rosacea, acne vulgaris or bullous pemphigoid.

22 more elements

Dependencies are inferred from the claim text.

Facts

Application: 16/834,607Filed 30 Mar 2020
Priority: 7 Dec 2007
Published: 20 Aug 2020
Term ends: Not estimatedThe source records don’t support an estimate.

Classification22 codes

C07K 16/244
Against cytokines, lymphokines or interferons: interleukins [IL]
A61K 39/00114
Cytokines: interleukins [IL]
A61P 17/00
Drugs for dermatological disorders
A61P 17/04
Drugs for dermatological disorders: antipruritics

Family

Application61/012,362Us provisional application · filed 7 Dec 2007
Application12/329,820Division · filed 8 Dec 2008
Application13/908,436Continuation · filed 3 Jun 2013
Application14/174,870Division · filed 7 Feb 2014
Application14/645,769Division · filed 12 Mar 2015
Application15/208,990Division · filed 13 Jul 2016
Application15/648,252Division · filed 12 Jul 2017
Application15/963,497Division · filed 26 Apr 2018
Application16/834,607Division
Application14/174,870Continuation
Application13/908,436Division
US 10,640,559 B2Related patent
US 11,542,327 B2Related patent
US 2009/0208494 A1Published application
US 2013/0295611 A1Published application
US 2014/0186891 A1Published application
US 2015/0183868 A1Published application
US 2016/0311898 A1Published application
US 2017/0313768 A1Published application
US 2018/0305448 A1Published application
US 8,470,979 B2Related patent
US 8,685,669 B2Related patent
US 9,005,921 B2Related patent
US 9,416,184 B2Related patent
US 9,738,715 B2Related patent
US 9,982,044 B2Related patent
US 2020/0262913 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

wherein the heavy chain variable domain complementarity determining region comprises:
a) a CDR1 having the amino acid sequence of SEQ ID NO:1;
b) a CDR2 having the amino acid sequence of SEQ ID NO:2;
and
c) a CDR3 having the amino acid sequence of SEQ ID NO:3;
wherein the heavy chain variable domain framework region comprises:
d) a FR1 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:12;
e) a FR2 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:13;
f) a FR3 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:14;
and
g) a FR4 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:15;
wherein the wherein the light chain variable domain complementarity determining region comprises:
h) a CDR1 having the amino acid sequence of SEQ ID NO:5;
i) a CDR2 having the amino acid sequence of SEQ ID NO:6;
and
j) a CDR3 having the amino acid sequence of SEQ ID NO:7;
wherein the light chain variable domain framework region comprises:
k) a FR5 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:17;
l) a FR6 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:18;
m) a FR7 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:19;
and
n) a FR8 having at least 90% sequence identity with amino acid sequence of SEQ ID NO:20;
and
wherein the pruritic disease is atopic dermatitis, contact dermatitis, dermatitis, prurigo nodularis, eczema, vitiligo, alopecia aerata, acne rosacea, acne vulgaris or bullous pemphigoid.